Article Text

Download PDFPDF
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)
  1. D. S. Alberts*,
  2. P. Y. Liu,
  3. S. P. Wilczynski,
  4. A. Jang§,
  5. J. Moon,
  6. J. H. Ward,
  7. J. T. Beck,
  8. M. Clouser* and
  9. M. Markman#
  1. *Arizona Cancer Center, University of Arizona, Tucson, Arizona;
  2. Southwest Oncology Group Statistical Center, Seattle, Washington;
  3. City of Hope National Medical Center, Duarte, California;
  4. §Southern California Permanente Medical Group, Riverside, California;
  5. University of Utah Health Science Center, Salt Lake City, Utah;
  6. University of Arkansas for Medical Science, Little Rock, Arkansas; and
  7. #MD Anderson Cancer Center, Houston, Texas
  1. Address correspondence and reprint requests to: David S. Alberts, MD, Arizona Cancer Center, University of Arizona, Box 245024, 1515 North Campbell Avenue, Tucson, AZ 85724-5024, USA. Email: dalberts{at}; Southwest Oncology Group (SO211), Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217, USA.


Platinum-resistant ovarian cancer continues to be a difficult therapeutic problem. Clearly, molecularly targeted agents should be evaluated in this patient population. Patients were eligible for this phase II study with stage III or IV ovarian cancer, whose tumor expressed Kit (CD117) or platelet-derived growth factor receptor (PDGFR) and with relapse of measurable disease within 6 months of completing frontline, platinum- and taxane-based chemotherapy. Patients were treated daily with 400 mg of imatinib mesylate orally. It was assumed that the agent would be of no further interest if the population response rate was less than 10%. A two-stage design was used for patient accrual. A total of 34 patients were registered to the study. Of these, 15 were found to be ineligible or not evaluable (8 because their tumor samples were negative for both DC117 and PDGFR). Of 19 evaluable patients, 2 (11%) tested positively for c-Kit and 17 (89%) tested positively for PDGFR. There were no objective responders. Thirteen patients (68%) had increasing disease or symptomatic deterioration, and six (32%) went off protocol during the first month due to adverse events. Median progression-free survival was 2 months (95% CI 1–3 months) and median overall survival was 10 months (95% CI 6–18 months). Eleven percent of patients experienced grade 4 hematologic/metabolic toxicity and 37% experienced grade 3 nonhematologic toxicity. We conclude that imatinib mesylate as a single agent does not appear to have useful clinical activity in c-Kit and/or PDGFR positive, recurrent ovarian cancer in heavily pretreated patients with ovarian cancer

  • imatinib mesylate
  • Kit (CD117)
  • ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.